New Delhi, July 20 -- Emcure Pharmaceuticals on Monday said its obesity drug brand Poviztra will now be available for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) after the Central Drugs Standard Control Organization (CDSCO) approved the new indication, making semaglutide the first and only GLP-1 receptor agonist approved in India for the progressive liver disease.

The company said the approval allows Poviztra, its co-marketed brand of innovator semaglutide (rDNA origin), to be used for treating non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3).

The announcement was made through a company press release submitted to stock exchanges.

"The approval for MASH marks an important milesto...